CoChat

Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma

Open access
Parra, Edwin R., Villalobos, Pamela, Mino, Barbara, Rodriguez-Canales, Jaime · 2018 · Applied Immunohistochemistry & Molecular Morphology
Cited by 155

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Programmed cell death ligand 1 (PD-L1) is a major immune checkpoint protein that mediates antitumor immune suppression and response. Preliminary data suggest that its detection using immunohistochemistry (IHC) in formalin-fixed and paraffin-embedded tissues may predict clinical response to PD-1/PD-L1 therapy. In diagnostic pathology, it is essential to count with a validated IHC that can reliably detect PD-L1-positive cases. The present study was conducted to compare and validate different PD-L1 commercial clones and identify which ones can be reliably used by surgical pathologist to detect PD-L1 expression in human cancer tissues. Eight commercial available PD-L1 clones were tested and compared with a noncommercial PD-L1 antibody clone 5H1. Western blot and IHC using cell lines and human tissues were used to validate these clones. From all PD-L1 antibodies, only the clones E1L3N, E1J2J, SP142, 28-8, 22C3, and SP263 passed the Western blot and IHC validation, providing similar pattern than the clone 5H1 and then they were tested in 259 non–small cell lung cancer cases placed in 9 tissue microarrays. Among all cases, only those with ≥2 cores were included (185 cases). Positive and significant correlation was found between the median PD-L1 H-score in tumor and stroma compartments, for all selected antibodies. Overall, 56 of 185 cases were detected as positive cases in malignant cells expressing membranous PD-L1 by all the clones. However, the clone SP263 identified more PD-L1-positive cases compared with the other clones. Our results show that clones E1L3N, E1J2J, SP142, 28-8, 22C3, and SP263 provide positive membrane staining pattern comparable with clone 5H1. These commercial clones are comparable, but a careful evaluation by the pathologist is necessary to minimize error of positive misinterpretations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/pai.0000000000000531

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 40

  1. Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 · DOI · Paper page
  2. Ribas, 2014, The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade, Clin Cancer Res, 20, 4982, 10.1158/1078-0432.CCR-14-0933 · DOI · Paper page
  3. Carreno, 2002, The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses, Annu Rev Immunol, 20, 29, 10.1146/annurev.immunol.20.091101.091806 · DOI · Paper page
  4. Sharpe, 2007, The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection, Nat Immunol, 8, 239, 10.1038/ni1443 · DOI · Paper page
  5. Guleria, 2005, A critical role for the programmed death ligand 1 in fetomaternal tolerance, J Exp Med, 202, 231, 10.1084/jem.20050019 · DOI · Paper page
  6. Watson, 2006, Differential effects of costimulatory pathway modulation on corneal allograft survival, Invest Ophthalmol Vis Sci, 47, 3417, 10.1167/iovs.05-1597 · DOI
  7. Sugita, 2009, Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism, Invest Ophthalmol Vis Sci, 50, 263, 10.1167/iovs.08-2536 · DOI
  8. Sheppard, 2004, PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3 zeta signalosome and downstream signaling to PKC theta, FEBS Lett, 574, 37, 10.1016/j.febslet.2004.07.083 · DOI · Paper page
  9. Eggermont, 2014, Cutaneous melanoma, Lancet, 383, 816, 10.1016/S0140-6736(13)60802-8 · DOI · Paper page
  10. Droeser, 2013, Clinical impact of programmed cell death ligand 1 expression in colorectal cancer, Eur J Cancer, 49, 2233, 10.1016/j.ejca.2013.02.015 · DOI · Paper page
  11. Ghebeh, 2006, The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, 8, 190, 10.1593/neo.05733 · DOI · Paper page
  12. Bigelow, 2013, Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue, J Vis Exp, 71, e4059
  13. Lin, 2014, Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for non-small cell lung cancer, Zhongguo fei ai za zhi, 17, 734
  14. Parra, 2016, Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients, Clin Cancer Res, 22, 6278, 10.1158/1078-0432.CCR-15-2443 · DOI · Paper page
  15. Sznol, 2013, Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer—response, Clin Cancer Res, 19, 1021, 10.1158/1078-0432.CCR-12-2063 · DOI · Paper page
  16. Berghoff, 2014, PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL), Clin Neuropathol, 33, 42, 10.5414/NP300698 · DOI · Paper page
  17. Bordeaux, 2010, Antibody validation, Biotechniques, 48, 197, 10.2144/000113382 · DOI · Paper page
  18. Rimm, 2014, Unvalidated antibodies and misleading results, Breast Cancer Res Treat, 147, 457, 10.1007/s10549-014-3061-0 · DOI
  19. Ilie, 2016, Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients, Virchows Arch, 468, 511, 10.1007/s00428-016-1910-4 · DOI · Paper page
  20. Boland, 2013, Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung, Clin Lung Cancer, 14, 157, 10.1016/j.cllc.2012.05.006 · DOI · Paper page
  21. Kim, 2015, Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers, Lung Cancer, 88, 24, 10.1016/j.lungcan.2015.01.016 · DOI · Paper page
  22. Guo, 2013, Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC, J Thorac Oncol, 8, 301, 10.1097/JTO.0b013e318282def7 · DOI
  23. Howat, 2014, Antibody validation of immunohistochemistry for biomarker discovery: recommendations of a consortium of academic and pharmaceutical based histopathology researchers, Methods, 70, 34, 10.1016/j.ymeth.2014.01.018 · DOI · Paper page
  24. Algenas, 2014, Antibody performance in western blot applications is context-dependent, Biotechnol J, 9, 435, 10.1002/biot.201300341 · DOI
  25. Thompson, 2005, B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma, Urology, 66, 10, 10.1016/j.urology.2005.06.010 · DOI
  26. Thompson, 2007, Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy, Clin Cancer Res, 13, 709s, 10.1158/1078-0432.CCR-06-1868 · DOI · Paper page
  27. Karim, 2009, Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma, Clin Cancer Res, 15, 6341, 10.1158/1078-0432.CCR-09-1652 · DOI · Paper page
  28. Topalian, 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Curr Opin Immunol, 24, 207, 10.1016/j.coi.2011.12.009 · DOI · Paper page
  29. Kerr, 2016, Non-small cell lung cancer, PD-L1, and the pathologist, Arch Pathol Lab Med, 140, 249, 10.5858/arpa.2015-0303-SA · DOI · Paper page
  30. Konishi, 2004, B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression, Clin Cancer Res, 10, 5094, 10.1158/1078-0432.CCR-04-0428 · DOI · Paper page
  31. Velcheti, 2014, Programmed death ligand-1 expression in non-small cell lung cancer, Lab Invest, 94, 107, 10.1038/labinvest.2013.130 · DOI · Paper page
  32. Kerr, 2015, Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?, J Thorac Oncol, 10, 985, 10.1097/JTO.0000000000000526 · DOI · Paper page
  33. D'Incecco, 2015, PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, Br J Cancer, 112, 95, 10.1038/bjc.2014.555 · DOI · Paper page
  34. Yang, 2014, Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes, Eur J Cancer, 50, 1361, 10.1016/j.ejca.2014.01.018 · DOI · Paper page
  35. Gatalica, 2014, Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type, Cancer Epidemiol Biomarkers Prev, 23, 2965, 10.1158/1055-9965.EPI-14-0654 · DOI · Paper page
  36. Smith, 2016, Quantitative and qualitative characterization of two PD-L1 clones: SP263 and E1L3N, Diagn Pathol, 11, 44, 10.1186/s13000-016-0494-2 · DOI
  37. Karlsson, 2011, Effects of long-term storage on the detection of proteins, DNA, and mRNA in tissue microarray slides, J Histochem Cytochem, 59, 1113, 10.1369/0022155411423779 · DOI
  38. Cree, 2016, PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation, Histopathology, 69, 177, 10.1111/his.12996 · DOI
  39. Sholl, 2016, Programmed death ligand-1 immunohistochemistry—a new challenge for pathologists: a perspective from members of the Pulmonary Pathology Society, Arch Pathol Lab Med, 140, 341, 10.5858/arpa.2015-0506-SA · DOI
  40. Rehman, 2017, Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer, Modern Pathol, 30, 340, 10.1038/modpathol.2016.186 · DOI · Paper page

Cited by

See all 155

Metadata

Authors
Parra, E. R., Villalobos, P., Mino, B., & Rodriguez-Canales, J.
Venue
Applied Immunohistochemistry & Molecular Morphology
Published
2018-02
Volume
26
Issue
2
Pages
83-93
ISSN
  • 1533-4058 (ISSN-L)
  • 1541-2016
OpenAlex
W2738111927
Cited by
155
References
11
FWCI
7.86
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma. https://app.cochat.ai/papers/10.1097/pai.0000000000000531
The paper
Parra, E. R., Villalobos, P., Mino, B., & Rodriguez-Canales, J. (2018). Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma. Applied Immunohistochemistry & Molecular Morphology. https://doi.org/10.1097/pai.0000000000000531

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.